Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc.

XENENYSE / NASDAQHealthcareSmall cap

$37.04-$0.52 (-1.4%)

Last close · Data as of Nov 20, 2026

Market cap
$5.1B
P/E
-14.8x
EV / EBITDA
-13.3x
Revenue
$7.5M
Net margin
-4612.1%
ROCE
-63.1%

-8.0% over the last year

Xenon Pharmaceuticals Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+2.1%
3M
-38.0%
6M
-32.3%
1Y
-8.0%
5Y
+27.8%

52-week range

Day change -$0.52 (-1.4%) from $38 to $37 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in XENE, bought on each weekday since 2021.

News & filings

What Xenon Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 346 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

Read moreShow less

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Sector
Healthcare
Shares outstanding
80.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.1B
P/E
-14.8x
P/B
8.8x
EV / EBITDA
-13.3x
EV / Sales
657.5x
P/S
683.0x
52-week high
$70.96
52-week low
$33.49

Profitability

Operating margin
-4974.3%
Net margin
-4612.1%
EBITDA margin
-4940.4%
ROE
-59.5%
ROCE
-63.1%
ROIC
-75.5%
ROA
-54.6%
Asset turnover
0.01

Growth

Revenue
$7.5M
Revenue CAGR, 3Y
-7.4%
Net profit growth, 1Y
47.6%
Free cash flow
-$279.9M

Solvency

Current ratio
13.42
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.81
Cash / Market cap
3.9%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$7.5M
Gross profit$7.5M
Operating expenses$380.6M
Research and development$300.9M
Selling, general and administrative$79.6M
Operating income-$373.1M
Interest and other$28.2M
Pretax income-$344.9M
Tax and other$1.0M
Net income-$345.9M

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Xenon Pharmaceuticals Inc. revenue and net profit by fiscal year
Xenon Pharmaceuticals Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$9.4M-$125.4M
FY2023$0.00-$182.4M
FY2024$0.00-$234.3M
FY2025$7.5M-$345.9M

Cash flows

FY2025: -$279.1M from operations, -$279.9M free after investment (dashed).

Xenon Pharmaceuticals Inc. operating and free cash flow by fiscal year
Xenon Pharmaceuticals Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$101.0M-$103.9M
FY2023-$151.1M-$156.7M
FY2024-$181.4M-$184.5M
FY2025-$279.1M-$279.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$7.5M
EBITDA
-$370.5M
Net profit
-$345.9M
Cash from operations
-$279.1M
Free cash flow
-$279.9M
Revenue CAGR, 3Y
-7.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$7.5M-$370.5M-$345.9M-$279.9M-59.5%—+47.6%

Monthly returns

Month-by-month returns of XENE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$633.2M
Liabilities$51.4M
Equity$581.8M
Paid-in capital$228.2M
Retained earnings-$1.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; XENE highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Xenon Pharmaceuticals Inc. (this company)657.5x

Not shown (no positive earnings and no EV / Sales): Cogent Biosciences, Inc., CRISPR Therapeutics AG, Scholar Rock Holding Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Xenon Pharmaceuticals Inc.XENEthis company$5.1B-14.8x8.8x-59.5%-13.3x
Mirum Pharmaceuticals, Inc.MIRM$5.6B-241.4x17.9x-7.4%329.1x
Cogent Biosciences, Inc.COGT$5.6B-17.0x10.2x-60.1%-17.2x
Liquidia CorporationLQDA$5.6B-80.7x124.3x-154.0%-128.8x
CRISPR Therapeutics AGCRSP$5.5B—2.9x-30.3%—
Scholar Rock Holding CorporationSRRK$5.4B—22.1x-154.0%—
CG Oncology, Inc.CGON$4.9B-30.7x6.6x-21.4%-26.0x
Twist Bioscience CorporationTWST$4.6B-59.3x9.7x-16.4%-40.4x
Dianthus Therapeutics, Inc.DNTH$4.6B-28.3x9.3x-32.9%-25.6x
Peer median—-45.0x10.0x-31.6%-25.8x

Year-to-date ROI

XENE since 1 January, against earlier years.

Historical volatility

XENE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Xenon Pharmaceuticals Inc. operating margin by fiscal year
Xenon Pharmaceuticals Inc. operating margin by fiscal year
DateOperating margin
FY2022-1369.5%
FY2023—
FY2024—
FY2025-4974.3%
LineFY2025
Operating expensesOperating Expense$380.6M
Research and developmentResearch And Development$300.9M
Total expensesTotal Expenses$380.6M
Pretax incomePretax Income-$344.9M

Learn while you research

Academy chapters picked for Xenon Pharmaceuticals Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →